Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | euchromatic histone-lysine N-methyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Onchocerca volvulus | Get druggable targets OG5_131470 | All targets in OG5_131470 | |
Brugia malayi | Pre-SET motif family protein | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Trichomonas vaginalis | set domain proteins, putative | Get druggable targets OG5_131470 | All targets in OG5_131470 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | histone lysine N methyltransferase SETMAR | 0.0036 | 0 | 0.5 |
Schistosoma mansoni | cytochrome b | 0.0505 | 1 | 1 |
Brugia malayi | Pre-SET motif family protein | 0.0251 | 0.4589 | 0.4589 |
Loa Loa (eye worm) | cytochrome b | 0.0505 | 1 | 1 |
Trichomonas vaginalis | set domain proteins, putative | 0.0286 | 0.5329 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | cytochrome b subunit of the bc complex | 0.0505 | 1 | 0.5 |
Plasmodium falciparum | cytochrome b | 0.0505 | 1 | 0.5 |
Schistosoma mansoni | cytochrome b | 0.0505 | 1 | 1 |
Plasmodium vivax | cytochrome b | 0.0505 | 1 | 1 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.0251 | 0.4589 | 0.4589 |
Onchocerca volvulus | 0.0286 | 0.5329 | 1 | |
Echinococcus granulosus | cytochrome B | 0.0505 | 1 | 1 |
Echinococcus multilocularis | histone lysine methyltransferase setb histone lysine methyltransferase eggless | 0.0036 | 0 | 0.5 |
Toxoplasma gondii | apocytochrome b, putative | 0.0505 | 1 | 1 |
Toxoplasma gondii | cytochrome b | 0.0505 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 53 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule agonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
IC50 (functional) | > 47.1 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS hits for small molecule antagonists of the CRF-binding protein and CRF-R2 receptor complex. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.1778 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.